

Market insights summary

# United States transcatheter mitral and tricuspid valve device markets

## What's trending and new

### 01. Availability of novel transcatheter mitral and tricuspid valve devices

- Abbott Laboratories introduced its Tendyne TMVI<sup>1</sup> device in May 2025, the first of its kind to be approved in the US.
- Edwards Lifesciences received FDA<sup>2</sup> approval for its SAPIEN M3 TMVI device in December 2025, limited to patients ineligible for other types of mitral surgery.
- Abbott Laboratories also launched its MitraClip G5 TMVR<sup>3</sup> and TriClip G5 TTVR<sup>4</sup> systems in August 2025, with increased ease-of-use and precision noted as key improvements over the previous iterations of these devices.

### 02. Reimbursement approvals and expanding device pipelines are accelerating growth in transcatheter mitral and tricuspid valves

- TTVI<sup>5</sup> and TTVR (TEER<sup>6</sup>) devices received approval for CMS<sup>7</sup> reimbursement coverage in March and July 2025, respectively. This is expected to contribute to the already strong growth within this segment.
- Other companies have transcatheter mitral and/or tricuspid therapies in development, including Medtronic's Intrepid TMVI and TTVI devices, which are expected to be available in the US in 2027.
- Non-TEER TMVR is also expected to enter the market in the coming years, including the HARPOON device from Edwards Lifesciences, CARILLON from Cardiac Dimensions, and DS1000 from NeoChord.

Access more insights and data in the [report](#). [Speak to our team](#) to see how we can power your innovation.

<sup>1</sup>TMVI = Transcatheter Mitral Valve Implantation  
<sup>2</sup>FDA = Food and Drug Administration (US)  
<sup>3</sup>TMVR = Transcatheter Mitral Valve Repair  
<sup>4</sup>TTVR = Transcatheter Tricuspid Valve Repair  
<sup>5</sup>TTVI = Transcatheter Tricuspid Valve Implantation  
<sup>6</sup>TEER = Transcatheter Edge-to-Edge Repair  
<sup>7</sup>CMS = Centers for Medicare & Medicaid Services

## 2024 U.S. transcatheter mitral and tricuspid valve device market snapshot


**\$644M**

Market revenue


**16.3%**

CAGR ('19-'34)

### U.S. transcatheter mitral and tricuspid valve device market



### 2024 U.S. transcatheter mitral and tricuspid valve competitive landscape



### Abbott Laboratories

- Abbott Laboratories remains the market leader for transcatheter repair devices due to continued uptake of its MitraClip TMVR device and TriClip TTVR device.
- Although it has not yet entered the TTVI device market, its recently released Tendyne TMVI device will continue to solidify its position as the market leader in transcatheter mitral valve therapies. However, it is expected to face increasing competition from Edwards Lifesciences in this segment in coming years.

### Edwards Lifesciences

- Edwards Lifesciences continues to lead the U.S. market for transcatheter mitral and tricuspid valve devices, supported by its EVOQUE and PASCAL series of replacement devices and repair devices.
- Recent approval of the Sapien M3 TMVI device is expected to expand its share in the overall transcatheter mitral valve device market.
- Edwards Lifesciences also has the EVOQUE Eos TMVI device in development.